Combination Chemotherapy and Antithymocyte Globulin in Reducing Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplantation For Myelodysplastic Syndrome or Myeloproliferative Disorder

PHASE1/PHASE2CompletedINTERVENTIONAL

Timeline

Start Date

October 31, 2002

Study Completion Date

September 30, 2006

Conditions

Chronic Myeloproliferative DisordersGraft Versus Host DiseaseLeukemiaMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Diseases

Interventions

BIOLOGICAL

anti-thymocyte globulin

DRUG

busulfan

DRUG

cyclophosphamide

DRUG

cyclosporine

DRUG

methotrexate

PROCEDURE

allogeneic bone marrow transplantation

PROCEDURE

peripheral blood stem cell transplantation

Trial Locations (1)

98109

Fred Hutchinson Cancer Research Center, Seattle

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Fred Hutchinson Cancer Center

OTHER

NCT00054340 - Combination Chemotherapy and Antithymocyte Globulin in Reducing Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplantation For Myelodysplastic Syndrome or Myeloproliferative Disorder | Biotech Hunter | Biotech Hunter